Drugs / ZETELETINIB
ZETELETINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03780517 | Dec 2018 → Sep 2023 | — | Boston Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZETELETINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095497 ↗ |
| Known as | BOS172738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03780517 ↗ |
| Known as | CAXM-1190b | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095497 ↗ |
| Known as | DS-5010b | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095497 ↗ |
| Known as | Ret inhibitor ds-5010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095497 ↗ |
| Modality | Small molecule | — CHEMBL5095497 ↗ |
| Route | Oral | “receive oral BOS172738” NCT03780517 ↗ |